Friday, October 16, 2026

CPI at 3.3% Cuts Rate-Cut Odds to 1-in-3, Sending Cloud ETFs Down 22% and Triggering Defensive Rotation

March 2026 CPI jumped to 3.3% from 2.4% in February, leaving futures markets pricing just a 1-in-3 probability of a Fed cut this year. Ten-year Treasury yields near 4.23% have crushed cloud ETFs—WCLD down 22%, CLOD down 14%—while investors pivot to dividend-growers and strategic buyers circle rate-compressed infrastructure assets.

LM Salvado
LM Salvado

April 26, 2026

Source Trace Score5 source documents5 with a live linkVerifiability: Strong
CPI at 3.3% Cuts Rate-Cut Odds to 1-in-3, Sending Cloud ETFs Down 22% and Triggering Defensive Rotation
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

March 2026 CPI hit 3.3%, up from 2.4% in February, cutting odds of a Federal Reserve rate cut to 1-in-3 for the year.1 The 10-year Treasury yield holds near 4.23%, sustaining elevated borrowing costs across the economy.1

Cloud and AI equities are absorbing the worst of the repricing. WCLD has fallen 22% year-to-date. CLOD is down 14%. SKYY has lost 10%.2 These ETFs carry heavy allocations to high-multiple, low-current-earnings companies — exactly the names that lose the most value when discount rates stay elevated.

The mechanism is direct. When rates remain high, the present value of future cash flows falls. Companies priced on earnings two or three years out get hit hardest. Growth-at-any-price stops working.

Geopolitical risk compounds the damage. Uncertainty around the Iran-Hormuz corridor has amplified risk-off dynamics, pushing gold higher as investors trim exposure to volatile growth assets.1

The defensive rotation is clearly underway. Johnson & Johnson and Coca-Cola are drawing portfolio inflows as managers reprice for a prolonged higher-rate regime.1 Both offer predictable, growing dividends — cash flows that hold real value when Treasuries yield above 4%.

Real estate is attracting a different kind of capital. KKR and Brookfield have begun circling rate-sensitive infrastructure assets at compressed valuations.3 For long-horizon acquirers, the same environment that punished existing holders is now opening entry points unavailable during the low-rate era.

The implication for portfolio managers is direct. Duration risk — whether embedded in cloud software multiples or real estate cap rates — remains expensive in a 4%-plus yield environment. With base-case odds at 2-in-3 against any 2026 cut, there is no near-term catalyst for relief.1

The rotation toward cash-generating, low-multiple businesses is structural, not cyclical. Persistent inflation has reset the price of growth.

Source documents

Via News is a conduit. We point to the source documents behind this report — we don't replace them. Trace any claim to its source and decide what to trust. How we source

Source Trace Score5 source documents5 with a live linkVerifiability: Strong
  1. [1]News articleYahoo Finance· April 25, 2026
    3 Market Trends That Could Shape the Rest of 2026
  2. [2]News articleYahoo Finance· April 25, 2026
    3 Cloud Computing ETFs to Buy as Enterprise AI Spending Accelerates in 2026
  3. [3]News articleYahoo Finance· April 18, 2026
    Gold surges on Hormuz news: Here’s what comes next
  4. [4]News articleYahoo Finance· April 20, 2026
    Put $5,000 In These Dividend Giants and Earn Passive Income Every Quarter
  5. [5]News articleSeeking Alpha· April 18, 2026
    Real estate stocks surge alongside broader markets

In this story · Knowledge Files

LM Salvado
LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com